Disparate effects of calcium antagonists on renal microcirculation

Koichi Hayashi, Takahiko Nagahama, Kiyoshi Oka, Murray Epstein, Takao Saruta

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Although calcium antagonists reduce systemic blood pressure, the effects of calcium antagonists on renal preglomerular and postglomerular microcirculation have been suggested to differ. In the present study we examined the vasodilator action of dihydropyridine-type calcium antagonists, including nifedipine, nicardipine, amlodipine, and efonidipine, on afferent and efferent arterioles during angiotensin II (A-II)and norepinephrine (NE)-induced renal vasoconstriction. Isolated perfused hydronephrotic kidneys were used to directly visualize renal microcirculatory response to calcium antagonists. Both A-II and NE caused marked vasoconstriction of afferent (A-II, 27 ± 2% decrement; NE, 28 ± 2% decrement) and efferent arterioles (A-II, 25±4% decrement; NE, 22± 2% decrement). The subsequent addition of nifedipine, nicardipine, and amlodipine reversed the afferent arteriolar vasoconstriction in a dose-dependent manner, and elicited complete vasodilation at 10 -6 M. In contrast, efferent arteriolar vasoconstriction was relatively refractory to the dilator action of these calcium antagonists; maximal dilation observed at 10 -6 M was 21± 1% (A-II) and 22 ± 3% (NE) for nifedipine, 25 ± 3% (A-II) and 20 ± 6% (NE) for nicardipine, and 39 ± 6% (A-n) and 37 ± 3% (NE) for amlodipine. In striking contrast, efonidipine dilated not only afferent arterioles, but also efferent arterioles in a dose-dependent manner. At 10 -6 M, efonidipine completely inhibited the afferent (A-II, 89 ± 7% reversal; NE, 99 ± 8% reversal) and efferent arteriolar vasoconstriction (A-II, 93 ± 4% reversal; NE, 87 ± 9% reversal). These findings clearly demonstrate that calcium antagonists dilate the afferent arteriole. Unlike the effects on the afferent arteriole, efferent arteriolar responsiveness to calcium antagonists differ, depending on the type of calcium antagonist. The efonidipine-induced efferent arteriolar vasodilation is probably not related to voltageoperated calcium channels, and may act, in concert with blood pressure lowering effect, to ameliorate glomerular capillary hypertension.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalHypertension Research - Clinical and Experimental
Volume19
Issue number1
Publication statusPublished - 1996

Fingerprint

Microcirculation
Angiotensin II
Norepinephrine
Arterioles
Calcium
Kidney
Vasoconstriction
Nicardipine
Amlodipine
Nifedipine
Vasodilation
Blood Pressure
Calcium Channels
Vasodilator Agents
Dilatation
Hypertension
efonidipine

Keywords

  • Afferent arteriole
  • Calcium antagonists
  • Efferent arteriole
  • Hypertension
  • Renal circulation

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Hayashi, K., Nagahama, T., Oka, K., Epstein, M., & Saruta, T. (1996). Disparate effects of calcium antagonists on renal microcirculation. Hypertension Research - Clinical and Experimental, 19(1), 31-36.

Disparate effects of calcium antagonists on renal microcirculation. / Hayashi, Koichi; Nagahama, Takahiko; Oka, Kiyoshi; Epstein, Murray; Saruta, Takao.

In: Hypertension Research - Clinical and Experimental, Vol. 19, No. 1, 1996, p. 31-36.

Research output: Contribution to journalArticle

Hayashi, K, Nagahama, T, Oka, K, Epstein, M & Saruta, T 1996, 'Disparate effects of calcium antagonists on renal microcirculation', Hypertension Research - Clinical and Experimental, vol. 19, no. 1, pp. 31-36.
Hayashi, Koichi ; Nagahama, Takahiko ; Oka, Kiyoshi ; Epstein, Murray ; Saruta, Takao. / Disparate effects of calcium antagonists on renal microcirculation. In: Hypertension Research - Clinical and Experimental. 1996 ; Vol. 19, No. 1. pp. 31-36.
@article{989381d3388b49e2a53396388ffcb3c5,
title = "Disparate effects of calcium antagonists on renal microcirculation",
abstract = "Although calcium antagonists reduce systemic blood pressure, the effects of calcium antagonists on renal preglomerular and postglomerular microcirculation have been suggested to differ. In the present study we examined the vasodilator action of dihydropyridine-type calcium antagonists, including nifedipine, nicardipine, amlodipine, and efonidipine, on afferent and efferent arterioles during angiotensin II (A-II)and norepinephrine (NE)-induced renal vasoconstriction. Isolated perfused hydronephrotic kidneys were used to directly visualize renal microcirculatory response to calcium antagonists. Both A-II and NE caused marked vasoconstriction of afferent (A-II, 27 ± 2{\%} decrement; NE, 28 ± 2{\%} decrement) and efferent arterioles (A-II, 25±4{\%} decrement; NE, 22± 2{\%} decrement). The subsequent addition of nifedipine, nicardipine, and amlodipine reversed the afferent arteriolar vasoconstriction in a dose-dependent manner, and elicited complete vasodilation at 10 -6 M. In contrast, efferent arteriolar vasoconstriction was relatively refractory to the dilator action of these calcium antagonists; maximal dilation observed at 10 -6 M was 21± 1{\%} (A-II) and 22 ± 3{\%} (NE) for nifedipine, 25 ± 3{\%} (A-II) and 20 ± 6{\%} (NE) for nicardipine, and 39 ± 6{\%} (A-n) and 37 ± 3{\%} (NE) for amlodipine. In striking contrast, efonidipine dilated not only afferent arterioles, but also efferent arterioles in a dose-dependent manner. At 10 -6 M, efonidipine completely inhibited the afferent (A-II, 89 ± 7{\%} reversal; NE, 99 ± 8{\%} reversal) and efferent arteriolar vasoconstriction (A-II, 93 ± 4{\%} reversal; NE, 87 ± 9{\%} reversal). These findings clearly demonstrate that calcium antagonists dilate the afferent arteriole. Unlike the effects on the afferent arteriole, efferent arteriolar responsiveness to calcium antagonists differ, depending on the type of calcium antagonist. The efonidipine-induced efferent arteriolar vasodilation is probably not related to voltageoperated calcium channels, and may act, in concert with blood pressure lowering effect, to ameliorate glomerular capillary hypertension.",
keywords = "Afferent arteriole, Calcium antagonists, Efferent arteriole, Hypertension, Renal circulation",
author = "Koichi Hayashi and Takahiko Nagahama and Kiyoshi Oka and Murray Epstein and Takao Saruta",
year = "1996",
language = "English",
volume = "19",
pages = "31--36",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Disparate effects of calcium antagonists on renal microcirculation

AU - Hayashi, Koichi

AU - Nagahama, Takahiko

AU - Oka, Kiyoshi

AU - Epstein, Murray

AU - Saruta, Takao

PY - 1996

Y1 - 1996

N2 - Although calcium antagonists reduce systemic blood pressure, the effects of calcium antagonists on renal preglomerular and postglomerular microcirculation have been suggested to differ. In the present study we examined the vasodilator action of dihydropyridine-type calcium antagonists, including nifedipine, nicardipine, amlodipine, and efonidipine, on afferent and efferent arterioles during angiotensin II (A-II)and norepinephrine (NE)-induced renal vasoconstriction. Isolated perfused hydronephrotic kidneys were used to directly visualize renal microcirculatory response to calcium antagonists. Both A-II and NE caused marked vasoconstriction of afferent (A-II, 27 ± 2% decrement; NE, 28 ± 2% decrement) and efferent arterioles (A-II, 25±4% decrement; NE, 22± 2% decrement). The subsequent addition of nifedipine, nicardipine, and amlodipine reversed the afferent arteriolar vasoconstriction in a dose-dependent manner, and elicited complete vasodilation at 10 -6 M. In contrast, efferent arteriolar vasoconstriction was relatively refractory to the dilator action of these calcium antagonists; maximal dilation observed at 10 -6 M was 21± 1% (A-II) and 22 ± 3% (NE) for nifedipine, 25 ± 3% (A-II) and 20 ± 6% (NE) for nicardipine, and 39 ± 6% (A-n) and 37 ± 3% (NE) for amlodipine. In striking contrast, efonidipine dilated not only afferent arterioles, but also efferent arterioles in a dose-dependent manner. At 10 -6 M, efonidipine completely inhibited the afferent (A-II, 89 ± 7% reversal; NE, 99 ± 8% reversal) and efferent arteriolar vasoconstriction (A-II, 93 ± 4% reversal; NE, 87 ± 9% reversal). These findings clearly demonstrate that calcium antagonists dilate the afferent arteriole. Unlike the effects on the afferent arteriole, efferent arteriolar responsiveness to calcium antagonists differ, depending on the type of calcium antagonist. The efonidipine-induced efferent arteriolar vasodilation is probably not related to voltageoperated calcium channels, and may act, in concert with blood pressure lowering effect, to ameliorate glomerular capillary hypertension.

AB - Although calcium antagonists reduce systemic blood pressure, the effects of calcium antagonists on renal preglomerular and postglomerular microcirculation have been suggested to differ. In the present study we examined the vasodilator action of dihydropyridine-type calcium antagonists, including nifedipine, nicardipine, amlodipine, and efonidipine, on afferent and efferent arterioles during angiotensin II (A-II)and norepinephrine (NE)-induced renal vasoconstriction. Isolated perfused hydronephrotic kidneys were used to directly visualize renal microcirculatory response to calcium antagonists. Both A-II and NE caused marked vasoconstriction of afferent (A-II, 27 ± 2% decrement; NE, 28 ± 2% decrement) and efferent arterioles (A-II, 25±4% decrement; NE, 22± 2% decrement). The subsequent addition of nifedipine, nicardipine, and amlodipine reversed the afferent arteriolar vasoconstriction in a dose-dependent manner, and elicited complete vasodilation at 10 -6 M. In contrast, efferent arteriolar vasoconstriction was relatively refractory to the dilator action of these calcium antagonists; maximal dilation observed at 10 -6 M was 21± 1% (A-II) and 22 ± 3% (NE) for nifedipine, 25 ± 3% (A-II) and 20 ± 6% (NE) for nicardipine, and 39 ± 6% (A-n) and 37 ± 3% (NE) for amlodipine. In striking contrast, efonidipine dilated not only afferent arterioles, but also efferent arterioles in a dose-dependent manner. At 10 -6 M, efonidipine completely inhibited the afferent (A-II, 89 ± 7% reversal; NE, 99 ± 8% reversal) and efferent arteriolar vasoconstriction (A-II, 93 ± 4% reversal; NE, 87 ± 9% reversal). These findings clearly demonstrate that calcium antagonists dilate the afferent arteriole. Unlike the effects on the afferent arteriole, efferent arteriolar responsiveness to calcium antagonists differ, depending on the type of calcium antagonist. The efonidipine-induced efferent arteriolar vasodilation is probably not related to voltageoperated calcium channels, and may act, in concert with blood pressure lowering effect, to ameliorate glomerular capillary hypertension.

KW - Afferent arteriole

KW - Calcium antagonists

KW - Efferent arteriole

KW - Hypertension

KW - Renal circulation

UR - http://www.scopus.com/inward/record.url?scp=0029927951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029927951&partnerID=8YFLogxK

M3 - Article

C2 - 8829821

AN - SCOPUS:0029927951

VL - 19

SP - 31

EP - 36

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 1

ER -